Latest Chronic kidney disease Stories
A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication. The meta-analysis also suggests the data "were inconclusive" that intensive...
NEW YORK, May 22, 2012 /PRNewswire/ -- The 27th Annual Scientific Meeting of the American Society of Hypertension (ASH) will feature presentations of several late-breaking clinical trials, which will highlight the most recent advances in hypertension research. Dr. George Bakris, The University of Chicago Medicine and President of ASH, will present research on a new Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), and its effects on anemia, blood pressure and...
SUNNYVALE, Calif. and BELGRADE, Serbia, May 22, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, presented positive data from its Phase 2a clinical study of CLP1001. In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo. Data from the randomized, double-blind Phase 2a study were presented in an...
Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings indicate that the procedure might improve CKD patients' heart health. Overactivity of neurons in the sympathetic—or fight or flight—nervous system is very common in patients with CKD. It not only contributes to...
One type of open heart surgery is likely safer than the other for chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Open heart, or coronary artery bypass, surgery can be done two ways: on-pump or off-pump, depending on whether the patient is put on a heart-lung machine. Off-pump surgery allows a surgeon to perform a bypass without stopping the heart. This may help cut down on kidney...
(Ivanhoe Newswire )--Heart disease is not only the leading cause of death in the U.S, it’s also the top cause of death for people with chronic kidney disease (CKD). New research shows one type of open heart surgery is safer than another (in terms of both health and survival) for these patients. Open heart surgery can be done two ways. The first way is off-pump. With this technique a surgeon can perform a bypass without stopping the heart. This may help cut down on kidney injuries that...
MERCER ISLAND, Wash., May 16, 2012 /PRNewswire/ -- Liberty Dialysis (www.libertydialysis.com), owner and operator of more than 260 dialysis clinics nationwide, is celebrating its 1,000th patient to participate in its Peritoneal Dialysis (PD) program. Liberty Dialysis is known for its strong commitment to home therapies for End Stage kidney disease patients, making this a particularly special milestone for the company. The 1,000th PD patient was trained in just two weeks, by...
LAWRENCE, Mass., May 14, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One(TM) patient Nikolas Gieske of Mequon, Wisconsin, received a kidney transplant following four successful years of more frequent home hemodialysis with the System One. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) The freedom to do his dialysis treatments on his own schedule...
LAWRENCE, Mass., May 11, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq:NXTM), a leading manufacturer of innovative dialysis products, today commented on findings of the Chronic Disease Research Group (CDRG) study showing that patients receiving daily, or more frequent, home hemodialysis with the NxStage System One(TM) are more likely to receive a kidney transplant when compared with conventional thrice-weekly dialysis, particularly in patients not on the transplant waitlist...
MARKHAM, ON, May 11, 2012 /PRNewswire/ - Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules. In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. These findings, as well as two other presentations on CTAP101 Capsules, are being featured at the National Kidney...
